top of page
LATEST NEWS
Lexeo's One-Time Gene Therapy Cut Dangerous Heart Rhythms by 80% in PKP2 Heart Disease
Interim Phase I/II results for Lexeo's LX2020 show an 80% average drop in dangerous heart-rhythm runs at the higher dose, with heart biopsies showing the missing PKP2 protein restored. The FDA is open to a faster approval path.
3 hours ago3 min read


Every Gene Therapy Approval We've Covered: FDA Decisions 2025-2026
The FDA's list of approved gene therapies now stands at 33. Every approval and rejection Gene Tech Times has covered, and the pattern they show.
17 hours ago3 min read


CRISPR for Cholesterol and Triglycerides: Everything We've Covered
Gene editing is moving from rare disease to high cholesterol and high triglycerides. Every Gene Tech Times story on PCSK9 and ANGPTL3 editing, and the argument it starts.
17 hours ago3 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


Lexeo's One-Time Gene Therapy Cut Dangerous Heart Rhythms by 80% in PKP2 Heart Disease
Interim Phase I/II results for Lexeo's LX2020 show an 80% average drop in dangerous heart-rhythm runs at the higher dose, with heart biopsies showing the missing PKP2 protein restored. The FDA is open to a faster approval path.
3 hours ago


Gene Therapy for Huntington's Disease: Everything We've Covered
uniQure's AMT-130 is the first Huntington's gene therapy to reach the FDA with long-term data behind it. Every Gene Tech Times story on it, in order, with what to watch before the May 2027 decision.
17 hours ago


FDA Investigates Cancer Risk With Zolgensma After Vector DNA Found Next to a Tumor Gene
The FDA confirmed that Zolgensma's AAV vector inserted next to the GLI1 cancer gene in two children who developed tumors. Here's what was found and what it means for SMA families and AAV gene therapy.
Nov 7


FDA Grants Priority Review to uniQure's Huntington's Gene Therapy AMT-130, Decision Due May 2027
The FDA accepted uniQure's BLA for AMT-130 under accelerated approval with Priority Review and a May 1, 2027 decision date. It could become the first gene therapy for Huntington's disease.
Nov 7


Estuary Launches With $103 Million to Bring Gene Therapy to Polycystic Kidney Disease
Estuary Biotherapeutics launched with $103 million to develop one-time, kidney-directed AAV gene therapies for ADPKD, the most common inherited kidney disease. Here is how restoring polycystin proteins could stop, or even reverse, kidney cysts.
Oct 22


Optogenetic Gene Therapy Gives Some Blind Patients Back a Sense of Light
In the NEJM-published PIONEER trial, an algae-derived light-sensing gene plus amber-light goggles improved light sensitivity in 6 of 10 people with late-stage retinitis pigmentosa, and 4 of 8 got better at finding objects. Here is how optogenetics works.
Oct 11


Two Years In, Elevidys Shows Functional Benefit in Older Boys With Duchenne
Boys with Duchenne who received Elevidys between ages 8 and 12 kept more motor function over two years than matched untreated boys, Sarepta reported at the World Muscle Society Congress. Here is what the data show, and what they don't.
Oct 8


FDA Approves Fayuvi, the First Treatment for Sanfilippo Syndrome Type A
The FDA approved Ultragenyx's Fayuvi (UX111), an AAV9 gene therapy and the first treatment of any kind for Sanfilippo syndrome type A, often called childhood Alzheimer's. Here's how it works and what the data showed.
Sep 16


FDA Places New Clinical Hold on Regenxbio's Hunter Syndrome Gene Therapy
The FDA placed a clinical hold on Regenxbio's RGX-121 for Hunter syndrome after MRIs found spinal nodules in 5 of 48 patients, derailing plans to resubmit. Here's the science and the timeline.
Aug 23


FDA Reverses Course on uniQure's Huntington's Gene Therapy
In June 2026 the FDA agreed that three-year data for uniQure's AMT-130 could support accelerated approval for Huntington's disease, reversing its late-2025 stance. Here's the science and the regulatory drama.
Jun 16


A Gene Therapy for Dravet Syndrome Cuts Seizures and Supports Development
At ASGCT 2026, Encoded Therapeutics shared one-year data for ETX101, an AAV9 gene regulation therapy for Dravet syndrome that cut seizures by about 76% at the top dose. A pivotal study is now underway.
May 12


Gene Therapy Restores Enzyme Levels to Treat Hypophosphatasia - A More Permanent Treatment
Hypophosphatasia (HPP), or "soft bone disease" is a rare genetic disorder that impacts bone and tooth development, leading to weak bones and other health complications. For years, enzyme replacement therapy has been the only effective treatment for HPP. This therapy involves injecting asfotase alfa, an enzyme that replaces the missing one in patients’ bodies. However, these injections must be given three to six times a week, which can be challenging for many patients. While t
Feb 4, 2025


Two New CRISPR-Based Gene Therapies for Sickle Cell Anemia Approved by the FDA
The FDA recently approved two groundbreaking CRISPR-based gene therapies for curing Sickle Cell Disease (SCD): Casgevy - developed by Vertex Pharmaceuticals and CRISPR Therapeutics Lyfgenia - developed by Bluebird Bio By targeting the BCL11A gene, these therapies successfully correct SCD mutations and increase fetal hemoglobin (HbF) levels in patients. This is exciting news for patients and families living with this painful disease, as it presents a potential cure rather than
Mar 25, 2024
bottom of page


